Edition:
United States

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

1.86USD
21 Sep 2018
Change (% chg)

$-0.08 (-4.12%)
Prev Close
$1.94
Open
$1.93
Day's High
$1.93
Day's Low
$1.83
Volume
30,259
Avg. Vol
88,007
52-wk High
$4.09
52-wk Low
$1.52

Latest Key Developments (Source: Significant Developments)

Sierra Oncology Obtains Debt Facility From Silicon Valley Bank To Acquire And Advance Momelotinib
Wednesday, 22 Aug 2018 07:05am EDT 

Aug 22 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY OBTAINS DEBT FACILITY FROM SILICON VALLEY BANK TO ACQUIRE AND ADVANCE MOMELOTINIB.SIERRA ONCOLOGY - DEBT FACILITY INCLUDES UP TO $15 MILLION AVAILABLE IN THREE $5 MILLION TRANCHES.SIERRA ONCOLOGY - AN ADDITIONAL $25 MILLION IS POTENTIALLY AVAILABLE IN AN UNCOMMITTED INCREMENTAL FACILITY SUBJECT TO LENDER APPROVAL.  Full Article

Sierra Oncology Acquires Momelotinib From Gilead Sciences
Wednesday, 22 Aug 2018 07:00am EDT 

Aug 22 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY ACQUIRES MOMELOTINIB, AN INVESTIGATIONAL JANUS KINASE (JAK) 1/2 AND ACTIVIN RECEPTOR TYPE 1 (ACVR1) INHIBITOR FOR MYELOFIBROSIS, FROM GILEAD SCIENCES.SIERRA ONCOLOGY INC - WILL PAY GILEAD A $3 MILLION UPFRONT FEE FOR MOMELOTINIB AND POTENTIAL AGGREGATE MILESTONE PAYMENTS OF UP TO $195 MILLION.SIERRA ONCOLOGY INC - SIERRA WILL ASSUME ALL CURRENTLY ONGOING CLINICAL STUDIES WITH MOMELOTINIB FOLLOWING A TRANSITION PERIOD..SIERRA - TO ALSO PAY GILEAD ROYALTIES ON ANY SALES OF MOMELOTINIB, WHICH WILL BE TIERED BASED ON COMMERCIAL SUCCESS & RANGE FROM MID-TEENS TO HIGH-TWENTIES.  Full Article

Sierra Oncology Announces Pricing Of Public Offering Of Common Stock
Friday, 2 Mar 2018 09:03am EST 

March 2 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 19.0 MILLION COMMON SHARES PRICED AT $2.25PER SHARE.  Full Article

Sierra Oncology Announces Proposed Public Offering Of Common Stock
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SIERRA ONCOLOGY - INTENDS TO USE NET PROCEEDS FROM PUBLIC OFFERING TO FUND DEVELOPMENT OF ITS PRODUCT CANDIDATES, SRA737 AND SRA141.  Full Article

Sierra Oncology Reports Qtrly Loss Of $0.20 Per Share
Tuesday, 27 Feb 2018 07:10am EST 

Feb 27 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY REPORTS 2017 YEAR END RESULTS.SIERRA ONCOLOGY INC - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.20‍​.SIERRA ONCOLOGY - ‍BELIEVES EXISTING CASH, CASH EQUIVALENTS TO BE SUFFICIENT TO FUND CURRENT OPERATING PLANS THROUGH ABOUT MID-2019​.SIERRA ONCOLOGY INC - CASH AND CASH EQUIVALENTS TOTALED $100.3 MILLION AS OF DECEMBER 31, 2017, COMPARED TO $107.8 MILLION AS OF SEPTEMBER 30, 2017‍​.  Full Article

Sierra Oncology Significantly Expands Clinical Development Program
Tuesday, 27 Feb 2018 07:05am EST 

Sierra Oncology Inc ::SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM.SIERRA ONCOLOGY INC - ADDING NEW SRA737 MONOTHERAPY COHORT FOR CCNE1-DRIVEN OVARIAN CANCER.SIERRA ONCOLOGY INC - SRA141 IND SUBMISSION PLANNED IN H2 2018.SIERRA ONCOLOGY - ONGOING SRA737 CLINICAL STUDIES EXPANDED TO TARGET AGGREGATE ENROLLMENT OF 200 PATIENTS ACROSS TEN CANCER INDICATIONS.SIERRA ONCOLOGY - TO INITIATE PHASE 1B/2 TRIAL IN Q4 TO EVALUATE SRA737 WITH ZEJULA TO TREAT METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.SIERRA ONCOLOGY - EXPANDING NUMBER OF ACTIVE SITES RECRUITING PATIENTS INTO SRA737-01 PHASE 1/2 MONOTHERAPY TRIAL FROM 3 TO 15.SIERRA ONCOLOGY - MAJORITY OF REPORTED ADVERSE EVENTS IN SRA737-02 PHASE 1/2 LDG COMBINATION TRIAL HAVE BEEN GRADE 1 OR GRADE 2 IN SEVERITY.SIERRA ONCOLOGY - ONLY ONE GRADE 3 TREATMENT RELATED AE (NEUTROPENIA) WAS OBSERVED, AT 40 MG SRA737/300 MG/M(2) GEMCITABINE.  Full Article

Sierra Oncology reports net loss $0.19 per share
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Sierra Oncology Inc ::Sierra Oncology reports third quarter results.Qtrly ‍net loss per share, basic and diluted $0.19​.  Full Article

Sierra Oncology reports qtrly loss per share $‍0.20​
Thursday, 10 Aug 2017 07:00am EDT 

Aug 10 (Reuters) - Sierra Oncology Inc :Sierra Oncology reports second quarter 2017 results.‍on track to provide preliminary update from CHK1 inhibitor SRA737 clinical trials in early 2018​.‍$116.7 million cash at June 30, 2017 projected to fund current operating plans through approximately mid-2019​.Qtrly loss per share $‍0.20​.  Full Article

Sierra Oncology reports initial progress from phase 1 clinical trials of CHK1 inhibitor SRA737
Monday, 5 Jun 2017 07:00am EDT 

June 5 (Reuters) - Sierra Oncology Inc :Sierra oncology reports encouraging initial progress from ongoing phase 1 clinical trials of chk1 inhibitor sra737.Sierra oncology inc says sra737 has been well-tolerated to date.Sierra oncology inc - "no grade 2 or higher sra737-related adverse events have been reported".Sierra oncology inc says for phase 1 chemotherapy combination study, has concluded enrolment and study has transitioned to stage 2.Sierra oncology inc - sra737 development program remains on track.  Full Article

Sierra Oncology granted U.S., EU patents for CHK1 inhibitor SRA737
Tuesday, 30 May 2017 07:00am EDT 

May 30 (Reuters) - Sierra Oncology Inc :Sierra Oncology granted U.S. and EU patents for CHK1 inhibitor SRA737.  Full Article

BRIEF-Sierra Oncology Reports Qtrly Loss Per Share $0.19

* SIERRA ONCOLOGY INC - SRA737 MONOTHERAPY PHASE 1/2 TRIAL EXPANDED TO ENROLL CCNE1-DRIVEN OVARIAN CANCER COHORT